Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.88 Consensus PT from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned an average recommendation of “Hold” from the nineteen brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $8.88.

Several equities research analysts recently commented on the stock. Scotiabank cut their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Piper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Stifel Nicolaus decreased their price objective on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Royal Bank of Canada raised Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target for the company in a research note on Thursday, November 21st.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $7.50 on Monday. The stock has a market capitalization of $461.11 million, a price-to-earnings ratio of -1.14 and a beta of 0.82. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $22.34. The stock has a fifty day moving average of $6.95 and a 200-day moving average of $6.72.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, equities analysts forecast that Sage Therapeutics will post -3.52 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of large investors have recently bought and sold shares of the stock. Picton Mahoney Asset Management boosted its position in shares of Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Sage Therapeutics during the 4th quarter worth approximately $49,000. Ieq Capital LLC acquired a new position in Sage Therapeutics during the 4th quarter worth approximately $57,000. US Bancorp DE boosted its holdings in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 2,446 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.